Rocío-V. Gamboa-Cárdenas
Research Subjects
Research Interests
Rocío-V. Gamboa-Cárdenas has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Manuel Francisco Ugarte-Gil
Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru
6 shared publications - Graciela S. Alarcon
The University of Alabama at Birmingham
4 shared publications Graciela S. Alarcón
Division of Clinical Immunology and Rheumatology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL
4 shared publications- Bernardo Antonio Pons‐Estel
Rheumatology, Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Rosario, Argentina
3 shared publications - Cesar A. Pastor-Asurza
Department of Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen, Perú
3 shared publications - Mariela Medina
Universidad de Montemorelos
3 shared publications
Latest Publications
- 13 November 2025
- Published by Elsevier in The Lancet Rheumatology
- Vol. 8 (1) , e53-e65
Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis
- 13 November 2025
- Published by Elsevier in The Lancet Rheumatology
- Vol. 8 (1) , e53-e65
Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis
- 12 June 2022
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 28 (8) , 390-396
Predictors of Remission and Low Disease Activity in Rheumatoid Arthritis Patients
Background: Clinical remission is the goal in rheumatoid arthritis (RA) management; however, this can be difficult to achieve in several parts of the world. Our objective was to determine predictors of remission and remission/low disease activity (LDA) in RA. Methods: A longitudinal real-setting RA cohort was followed up (January 2016–2020). Predictors examined were sex, age at diagnosis, disease duration, socioeconomic status, tobacco use, rheumatoid factor titer, comorbidities (Charlson index), Simple Disease Activity Index (SDAI) score, disability (Multidimensional Disease Health Assessment Questionnaire), health-related quality of life (Short Form-36 questionnaire), glucocorticoid dose, biological/target synthetic disease-modifying antirheumatic drugs, and conventional DMARD (c-DMARD) use. Univariable and multivariable generalized estimating equation models were done to determine predictors of remission (at a given visit) and sustained remission (2 consecutives visits), using the SDAI definition (0 or p = 0.004) and current (OR, 2.293; 95% CI, 1.811–2.903; p < 0.001) or past (OR, 1.383; 95% CI, 1.127–1.698; p = 0.002) use of c-DMARDs predicted remission/LDA in at least 1 visit, whereas the SDAI (OR, 0.951; 95% CI, 0.942–0.959; p < 0.001), Multidimensional Disease Health Assessment Questionnaire (OR, 0.648; 95% CI, 0.549–0.764; p < 0.001), and age at diagnosis (OR, 0.994; 95% CI, 0.990–0.998; p = 0.004) were negative predictors. As to sustained remission/LDA, current (OR, 2.012; 95% CI, 1.458–2.776: p < 0.001) or past (OR, 1.517; 95% CI, 1.155–1.993; p = 0.003) use of c-DMARDs, having a better Short Form-36 questionnaire physical component summary (OR, 1.022; 95% CI, 1.014–1.029; p < 0.001), and older age at diagnosis (OR, 1.013; 95% CI, 1.003–1.022; p = 0.008) predicted it, whereas SDAI (OR, 0.949; 95% CI, 0.933–0.965; p < 0.001) and medium low/low socioeconomic status (OR, 0.674; 95% CI, 0.500–0.909; p = 0.010) were negative predictors. Conclusion: During follow-up of this real-world RA cohort, c-DMARD use predicted remission and remission/LDA. In contrast, disease activity was a negative predictor.
- 12 June 2022
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 28 (8) , 390-396
Predictors of Remission and Low Disease Activity in Rheumatoid Arthritis Patients
Background: Clinical remission is the goal in rheumatoid arthritis (RA) management; however, this can be difficult to achieve in several parts of the world. Our objective was to determine predictors of remission and remission/low disease activity (LDA) in RA. Methods: A longitudinal real-setting RA cohort was followed up (January 2016–2020). Predictors examined were sex, age at diagnosis, disease duration, socioeconomic status, tobacco use, rheumatoid factor titer, comorbidities (Charlson index), Simple Disease Activity Index (SDAI) score, disability (Multidimensional Disease Health Assessment Questionnaire), health-related quality of life (Short Form-36 questionnaire), glucocorticoid dose, biological/target synthetic disease-modifying antirheumatic drugs, and conventional DMARD (c-DMARD) use. Univariable and multivariable generalized estimating equation models were done to determine predictors of remission (at a given visit) and sustained remission (2 consecutives visits), using the SDAI definition (0 or p = 0.004) and current (OR, 2.293; 95% CI, 1.811–2.903; p < 0.001) or past (OR, 1.383; 95% CI, 1.127–1.698; p = 0.002) use of c-DMARDs predicted remission/LDA in at least 1 visit, whereas the SDAI (OR, 0.951; 95% CI, 0.942–0.959; p < 0.001), Multidimensional Disease Health Assessment Questionnaire (OR, 0.648; 95% CI, 0.549–0.764; p < 0.001), and age at diagnosis (OR, 0.994; 95% CI, 0.990–0.998; p = 0.004) were negative predictors. As to sustained remission/LDA, current (OR, 2.012; 95% CI, 1.458–2.776: p < 0.001) or past (OR, 1.517; 95% CI, 1.155–1.993; p = 0.003) use of c-DMARDs, having a better Short Form-36 questionnaire physical component summary (OR, 1.022; 95% CI, 1.014–1.029; p < 0.001), and older age at diagnosis (OR, 1.013; 95% CI, 1.003–1.022; p = 0.008) predicted it, whereas SDAI (OR, 0.949; 95% CI, 0.933–0.965; p < 0.001) and medium low/low socioeconomic status (OR, 0.674; 95% CI, 0.500–0.909; p = 0.010) were negative predictors. Conclusion: During follow-up of this real-world RA cohort, c-DMARD use predicted remission and remission/LDA. In contrast, disease activity was a negative predictor.
- 6 January 2022
- Published by SAGE Publications in Lupus
- Vol. 31 (1) , 105-109
Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort
This study aims to determine whether the MetS predicts damage accrual in SLE patients. This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients had a baseline visit and then follow-up visits every 6 months. Patients with ≥ 2 visits were included. Evaluations included interview, medical records review, physical examination, and laboratory tests. Damage accrual was ascertained with the SLICC/ACR damage index (SDI) and disease activity with the SLEDAI-2K. Univariable and multivariable Cox-regression survival models were carried out to determine the risk of developing new damage. The multivariable model was adjusted for age at diagnosis; disease duration; socioeconomic status; SLEDAI; baseline SDI; the Charlson Comorbidity Index; daily dose; and time of exposure of prednisone (PDN), antimalarials, and immunosuppressive drugs. Two hundred and forty-nine patients were evaluated; 232 of them were women (93.2%). Their mean (SD) age at diagnosis was 35.8 (13.1) years; nearly all patients were Mestizo. Disease duration was 7.4 (6.6) years. The SLEDAI-2K was 5.2 (4.3) and the SDI, 0.9 (1.3). One hundred and eight patients (43.4%) had MetS at baseline. During follow-up, 116 (46.6%) patients accrued at least one new point in the SDI damage index. In multivariable analyses, the presence of MetS was a predictor of the development of new damage (HR: 1.54 (1.05–2.26); p < 0.029). The presence of MetS predicts the development of new damage in SLE patients, despite other well-known risk factors for such occurrence.
- 6 January 2022
- Published by SAGE Publications in Lupus
- Vol. 31 (1) , 105-109
Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort
This study aims to determine whether the MetS predicts damage accrual in SLE patients. This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients had a baseline visit and then follow-up visits every 6 months. Patients with ≥ 2 visits were included. Evaluations included interview, medical records review, physical examination, and laboratory tests. Damage accrual was ascertained with the SLICC/ACR damage index (SDI) and disease activity with the SLEDAI-2K. Univariable and multivariable Cox-regression survival models were carried out to determine the risk of developing new damage. The multivariable model was adjusted for age at diagnosis; disease duration; socioeconomic status; SLEDAI; baseline SDI; the Charlson Comorbidity Index; daily dose; and time of exposure of prednisone (PDN), antimalarials, and immunosuppressive drugs. Two hundred and forty-nine patients were evaluated; 232 of them were women (93.2%). Their mean (SD) age at diagnosis was 35.8 (13.1) years; nearly all patients were Mestizo. Disease duration was 7.4 (6.6) years. The SLEDAI-2K was 5.2 (4.3) and the SDI, 0.9 (1.3). One hundred and eight patients (43.4%) had MetS at baseline. During follow-up, 116 (46.6%) patients accrued at least one new point in the SDI damage index. In multivariable analyses, the presence of MetS was a predictor of the development of new damage (HR: 1.54 (1.05–2.26); p < 0.029). The presence of MetS predicts the development of new damage in SLE patients, despite other well-known risk factors for such occurrence.
- 30 June 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (11) , 4725-4734
Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up
Objective The identification of risk factors for COVID-19 adverse course in autoimmune rheumatic diseases (ARDs) is of the utmost importance when approaching patient management; however, data are scarce in relation to the Latin American population. The objective of this study was to determine predictors of hospitalization for COVID-19 patients from an ARD community cohort. Methods A real setting longitudinal study (March to November 2020) in an ARD community cohort was carried out. Potential predictors of hospitalization for COVID-19 examined included (1) sociodemographic variables (age, gender, education, tobacco use, socioeconomic status, and co-inhabitants), (2) comorbidities, (3) time to COVID-19 diagnosis, and (4) ARD’s features: clinical (disease type, disease duration, activity), treatment [corticosteroids use/doses, use of synthetic DMARDs (cDMARDs, tsDMARDs, and bDMARDs)], treatment schedule and non-adherence, and the Multidimensional Health Assessment Questionnaire (MDHAQ). Univariable and multivariable regression analysis were conducted; OR and 95% CI (p < 0.05) were determined. Results One thousand and one hundred forty-eight patients with ARDs were included; 154 had COVID-19; of these 139 (90.3%) were women, aged 52.5 (13.7) years; 33.1% had hypertension and 61.0% an affected organ by ARD. Infection was detected 8.4 (10.1) days after symptoms started; there were 33 hospitalized patients (rate 21.4%). Predictors of hospitalization by multivariable analysis were age (OR: 1.06; CI: 1.01–1.10; p: 0.01), comorbidities: hypertension (OR: 3.95; 95% CI: 1.40–10.95, p: 0.01) and neoplasm (OR: 9.0; 95% CI: 1.6–52.3; p: 0.01), number of organs involved by ARD (OR: 2.26; 95% CI: 1.16–4.41; p: 0.02), and infection diagnosis delay (OR: 1.36; 95% CI: 1.03–1.80; p: 0.01). Conclusions In our ARD patients with COVID-19, older age, comorbidities (neoplasm and hypertension), and a delay in COVID-19 diagnosis were predictors of hospitalization. The only ARD-associated predictor feature was the number of organs involved. Key Points • Patients with ARD and COVID-19 have an adverse course in comparison to the general population. • Previous predictors of COVID-19 hospitalization, including known risk factors (such as older age and comorbidities) and systemic manifestations, should be taken into account in the management of these patients. • Delayed diagnosis of COVID-19 impacts negatively on prognosis. • Availability of diagnostic tests is of utmost importance.
- 30 June 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (11) , 4725-4734
Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up
Objective The identification of risk factors for COVID-19 adverse course in autoimmune rheumatic diseases (ARDs) is of the utmost importance when approaching patient management; however, data are scarce in relation to the Latin American population. The objective of this study was to determine predictors of hospitalization for COVID-19 patients from an ARD community cohort. Methods A real setting longitudinal study (March to November 2020) in an ARD community cohort was carried out. Potential predictors of hospitalization for COVID-19 examined included (1) sociodemographic variables (age, gender, education, tobacco use, socioeconomic status, and co-inhabitants), (2) comorbidities, (3) time to COVID-19 diagnosis, and (4) ARD’s features: clinical (disease type, disease duration, activity), treatment [corticosteroids use/doses, use of synthetic DMARDs (cDMARDs, tsDMARDs, and bDMARDs)], treatment schedule and non-adherence, and the Multidimensional Health Assessment Questionnaire (MDHAQ). Univariable and multivariable regression analysis were conducted; OR and 95% CI (p < 0.05) were determined. Results One thousand and one hundred forty-eight patients with ARDs were included; 154 had COVID-19; of these 139 (90.3%) were women, aged 52.5 (13.7) years; 33.1% had hypertension and 61.0% an affected organ by ARD. Infection was detected 8.4 (10.1) days after symptoms started; there were 33 hospitalized patients (rate 21.4%). Predictors of hospitalization by multivariable analysis were age (OR: 1.06; CI: 1.01–1.10; p: 0.01), comorbidities: hypertension (OR: 3.95; 95% CI: 1.40–10.95, p: 0.01) and neoplasm (OR: 9.0; 95% CI: 1.6–52.3; p: 0.01), number of organs involved by ARD (OR: 2.26; 95% CI: 1.16–4.41; p: 0.02), and infection diagnosis delay (OR: 1.36; 95% CI: 1.03–1.80; p: 0.01). Conclusions In our ARD patients with COVID-19, older age, comorbidities (neoplasm and hypertension), and a delay in COVID-19 diagnosis were predictors of hospitalization. The only ARD-associated predictor feature was the number of organs involved. Key Points • Patients with ARD and COVID-19 have an adverse course in comparison to the general population. • Previous predictors of COVID-19 hospitalization, including known risk factors (such as older age and comorbidities) and systemic manifestations, should be taken into account in the management of these patients. • Delayed diagnosis of COVID-19 impacts negatively on prognosis. • Availability of diagnostic tests is of utmost importance.
- Open Access
- 15 September 2020
- Published by Pan American League of Associations of Rheumatology (PANLAR) in Global Rheumatology
Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry
Objective: To compare the characteristics of patients with rheumatic diseases and COVID-19 reported from Latin American countries with those from the rest of the world. Methods: Patients from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry were included. Details regarding demographics, rheumatic disease features, comorbidities, COVID-19 diagnosis and treatment, and outcomes were examined. Chi-squared and t-tests were used to compare associations between groups (Latin America vs. rest of the world). Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of hospitalization (yes/no) and ventilatory support (not hospitalized or supplementary oxygen only vs. non-invasive, invasive ventilation, or ECMO); Poisson models were used to estimate ORs and 95% CIs of mortality. Results: Seventy-four patients from Latin America and 583 patients from the rest of the world were included. The most frequent rheumatic diseases in both groups were rheumatoid arthritis (35% and 39%, respectively) and systemic lupus erythematosus (22% and 14% respectively). Mortality was similar between groups (12% Latin America vs 11% rest of the world, p=0.88. However, Latin American patients in the registry had a higher odds of requiring non-invasive or invasive ventilation, after adjustment [OR= 2.29, 95%CI (1.29, 4.07), p less than 0.01].. Conclusion: Latin American patients with rheumatic disease and COVID-19 reported to this global registry presented a higher need for ventilatory support, however experienced a similar mortality than patients from the rest of the world.
- 15 September 2020
- Published by Pan American League of Associations of Rheumatology (PANLAR) in Global Rheumatology
Open AccessCharacteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry
Objective: To compare the characteristics of patients with rheumatic diseases and COVID-19 reported from Latin American countries with those from the rest of the world. Methods: Patients from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry were included. Details regarding demographics, rheumatic disease features, comorbidities, COVID-19 diagnosis and treatment, and outcomes were examined. Chi-squared and t-tests were used to compare associations between groups (Latin America vs. rest of the world). Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of hospitalization (yes/no) and ventilatory support (not hospitalized or supplementary oxygen only vs. non-invasive, invasive ventilation, or ECMO); Poisson models were used to estimate ORs and 95% CIs of mortality. Results: Seventy-four patients from Latin America and 583 patients from the rest of the world were included. The most frequent rheumatic diseases in both groups were rheumatoid arthritis (35% and 39%, respectively) and systemic lupus erythematosus (22% and 14% respectively). Mortality was similar between groups (12% Latin America vs 11% rest of the world, p=0.88. However, Latin American patients in the registry had a higher odds of requiring non-invasive or invasive ventilation, after adjustment [OR= 2.29, 95%CI (1.29, 4.07), p less than 0.01].. Conclusion: Latin American patients with rheumatic disease and COVID-19 reported to this global registry presented a higher need for ventilatory support, however experienced a similar mortality than patients from the rest of the world.
- 24 September 2019
- Published by SAGE Publications in Lupus
- Vol. 28 (11) , 1344-1349
Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients
The aim of this study was to determine whether remission and low disease activity state protect systemic lupus erythematosus patients from being hospitalized. Patients from the Almenara Lupus Cohort were included. Visits were performed every 6 months. Variables were measured at each visit. Hospitalizations were evaluated in the interval between two visits. Remission was defined as: a SLEDAI-2 K of 0, prednisone ≤5 mg/day and immunosuppressants on maintenance dose; low disease activity state as: a SLEDAI-2 K of ≤4, prednisone ≤7.5 mg/day and immunosuppressants on maintenance dose. Univariable and multivariable interval-censored survival regression models were used. In multivariable analysis, possible confounders were gender, age at diagnosis, socioeconomic status, educational level, disease duration, antimalarial use, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI) and Charlson comorbidity index. Confounders were determined in the same visit as disease activity state. Of the 308 patients, 92.5% of them (n = 285) were women, had a mean age at diagnosis of 34.8 (13.4) years and a disease duration of 7.7 (6.5) years. At baseline the mean SDI was 1.13 (1.34). A total of 163 of the patients were hospitalized. In the multivariable analysis remission (hazard ratio 0.445 (0.274–0.725), P = 0.001) and low disease activity state (relative risk 0.504 (0.336–0.757), P = 0.001) at baseline were found to decrease the risk of hospitalization in systemic lupus erythematosus patients. A total of 158 hospitalizations presented a discernible cause. Disease activity was the most common cause of hospitalization, with 84 admissions (53.16%), the majority, 38, was due to active kidney disease (45.23%). Remission and low disease activity state decreased the risk of hospitalizations in these systemic lupus erythematosus patients. Disease activity, particularly renal, was the most frequent cause of hospitalization.
- 24 September 2019
- Published by SAGE Publications in Lupus
- Vol. 28 (11) , 1344-1349
Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients
The aim of this study was to determine whether remission and low disease activity state protect systemic lupus erythematosus patients from being hospitalized. Patients from the Almenara Lupus Cohort were included. Visits were performed every 6 months. Variables were measured at each visit. Hospitalizations were evaluated in the interval between two visits. Remission was defined as: a SLEDAI-2 K of 0, prednisone ≤5 mg/day and immunosuppressants on maintenance dose; low disease activity state as: a SLEDAI-2 K of ≤4, prednisone ≤7.5 mg/day and immunosuppressants on maintenance dose. Univariable and multivariable interval-censored survival regression models were used. In multivariable analysis, possible confounders were gender, age at diagnosis, socioeconomic status, educational level, disease duration, antimalarial use, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI) and Charlson comorbidity index. Confounders were determined in the same visit as disease activity state. Of the 308 patients, 92.5% of them (n = 285) were women, had a mean age at diagnosis of 34.8 (13.4) years and a disease duration of 7.7 (6.5) years. At baseline the mean SDI was 1.13 (1.34). A total of 163 of the patients were hospitalized. In the multivariable analysis remission (hazard ratio 0.445 (0.274–0.725), P = 0.001) and low disease activity state (relative risk 0.504 (0.336–0.757), P = 0.001) at baseline were found to decrease the risk of hospitalization in systemic lupus erythematosus patients. A total of 158 hospitalizations presented a discernible cause. Disease activity was the most common cause of hospitalization, with 84 admissions (53.16%), the majority, 38, was due to active kidney disease (45.23%). Remission and low disease activity state decreased the risk of hospitalizations in these systemic lupus erythematosus patients. Disease activity, particularly renal, was the most frequent cause of hospitalization.
- 20 August 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (10) , 2963-2964
Correction to: Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort
The original version of this article, unfortunately, contained an error. The first and family name of Loreto Massardo was interchanged and is now presented correctly in this article.
- 20 August 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (10) , 2963-2964
Correction to: Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort
The original version of this article, unfortunately, contained an error. The first and family name of Loreto Massardo was interchanged and is now presented correctly in this article.
- 3 June 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (10) , 2737-2746
Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort
To identify baseline predictors of remission and low disease activity (LDA) in early rheumatoid arthritis (RA) from the GLADAR (Grupo Latino Americano De estudio de la Artritis Reumatoide) cohort.
- 3 June 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (10) , 2737-2746
Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort
To identify baseline predictors of remission and low disease activity (LDA) in early rheumatoid arthritis (RA) from the GLADAR (Grupo Latino Americano De estudio de la Artritis Reumatoide) cohort.
- 31 August 2017
- Published by SAGE Publications in Lupus
- Vol. 27 (4) , 536-544
Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort
The purpose of this paper is to determine the factors predictive of flares in systemic lupus erythematosus (SLE) patients. A case-control study nested within the Grupo Latino Americano De Estudio de Lupus (GLADEL) cohort was conducted. Flare was defined as an increase ≥4 points in the SLEDAI. Cases were defined as patients with at least one flare. Controls were selected by matching cases by length of follow-up. Demographic and clinical manifestations were systematically recorded by a common protocol. Glucocorticoid use was recorded as average daily dose of prednisone and antimalarial use as percentage of time on antimalarial and categorized as never (0%), rarely (>0–25%), occasionally (>25%–50%), commonly (˃50%–75%) and frequently (˃75%). Immunosuppressive drugs were recorded as used or not used. The association between demographic, clinical manifestations, therapy and flares was examined using univariable and multivariable conditional logistic regression models. A total of 465 cases and controls were included. Mean age at diagnosis among cases and controls was 27.5 vs 29.9 years, p = 0.003; gender and ethnic distributions were comparable among both groups and so was the baseline SLEDAI. Independent factors protective of flares identified by multivariable analysis were older age at diagnosis (OR = 0.929 per every five years, 95% CI 0.869–0.975; p = 0.004) and antimalarial use (frequently vs never, OR = 0.722, 95% CI 0.522–0.998; p = 0.049) whereas azathioprine use (OR = 1.820, 95% CI 1.309–2.531; p < 0.001) and SLEDAI post-baseline were predictive of them (OR = 1.034, 95% CI 1.005–1.064; p = 0.022). In this large, longitudinal Latin American cohort, older age at diagnosis and more frequent antimalarial use were protective whereas azathioprine use and higher disease activity were predictive of flares.
- 31 August 2017
- Published by SAGE Publications in Lupus
- Vol. 27 (4) , 536-544
Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort
The purpose of this paper is to determine the factors predictive of flares in systemic lupus erythematosus (SLE) patients. A case-control study nested within the Grupo Latino Americano De Estudio de Lupus (GLADEL) cohort was conducted. Flare was defined as an increase ≥4 points in the SLEDAI. Cases were defined as patients with at least one flare. Controls were selected by matching cases by length of follow-up. Demographic and clinical manifestations were systematically recorded by a common protocol. Glucocorticoid use was recorded as average daily dose of prednisone and antimalarial use as percentage of time on antimalarial and categorized as never (0%), rarely (>0–25%), occasionally (>25%–50%), commonly (˃50%–75%) and frequently (˃75%). Immunosuppressive drugs were recorded as used or not used. The association between demographic, clinical manifestations, therapy and flares was examined using univariable and multivariable conditional logistic regression models. A total of 465 cases and controls were included. Mean age at diagnosis among cases and controls was 27.5 vs 29.9 years, p = 0.003; gender and ethnic distributions were comparable among both groups and so was the baseline SLEDAI. Independent factors protective of flares identified by multivariable analysis were older age at diagnosis (OR = 0.929 per every five years, 95% CI 0.869–0.975; p = 0.004) and antimalarial use (frequently vs never, OR = 0.722, 95% CI 0.522–0.998; p = 0.049) whereas azathioprine use (OR = 1.820, 95% CI 1.309–2.531; p < 0.001) and SLEDAI post-baseline were predictive of them (OR = 1.034, 95% CI 1.005–1.064; p = 0.022). In this large, longitudinal Latin American cohort, older age at diagnosis and more frequent antimalarial use were protective whereas azathioprine use and higher disease activity were predictive of flares.
- 1 June 2015
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 74 (Suppl 2) , 1022-1023
AB0388 A Reduced Lean Body Mass is Associated with a More Severe Joint Damage in Patients with Rheumatoid Arthritis (RA)
Background In Rheumatoid Arthritis (RA) alterations in the amount and distribution of fat and lean mass result in abnormal body composition phenotypes probably as a consequence of persistent inflammatory state. Lower lean mass and the sarcopenia phenotype have been associated with disability previously. Objectives The aim of this study was to determine whether a reduced Lean Body Mass (LBM) is associated with a more severe joint damage in RA Methods A cross-sectional study, conducted in consecutive established RA woman patients seen in our Rheumatology Department between 2012 and 2014. RA was defined using the ACR 1987 criteria. Patients with overlap syndrome (except Sjogren), prosthetic or metallic elements, infections, trauma/ recent surgery, cancer, hospitalized, pregnant or weight>120 kg were excluded. An interview, chart review, physical examination and laboratory tests were performed. All subjects providing written informed consent. LBM was determined by dual X-ray absorptiometry (DXA) and was expressed as the LBM Index (kg/ m2). Joint damage (JD) was measure according to Sharp VD Heijde method (erosion, joint space narrowing and total score). The association between LBM and JD was evaluated using Pearson's correlation. Subsequently, a linear regression model was performed to evaluate the persistence of these association adjusted by age, age at diagnosis, disease duration, Socioeconomic status according to Graffar's scale, tobacco habit, ACPA title, disease activity using the DAS28 ESR, glucocorticoids use and functional capacity (MHAQ questionnaire) Results One hundred and seventy-four women patients were included. The average (SD) age was 57.7 (12.7) years. Disease duration was 14.4 (10.6) years; all patients were mestizo. ACPA title was 768.8 (1357.3) uM/L, DAS28 was 4.8 (1.3), the Sharp VD Heijde total score was 168 (93.6) and the Body Mass Index (BMI) was: 28.19 (4.81) kg/m2. The LBM was 6.03 kg/m2 (0.9) and the percentage of fat Body Mass (FBM) was 38.46 (4.56) In the univariate analysis, according to Pearson correlation Index, a lower LBM was associated with a more total (-0.27, p=0.00); erosion (-0.27, p=0.001) and space narrowing (-0.25, p=0.001) Sharp VDH scores. In the multivariate model adjusted by age, age at diagnosis, disease duration, Graffar's scale, tobacco, ACPA, DAS28, glucocorticoids use and MHAQ, these correlation persisted (erosion score: B: -0.010, p=0.002; space narrowing score: B: -0.012; p=0.002 and total score: B: -0.006 p=0.001) Conclusions A lower Lean Body Mass was associated with a more severe joint damage independently of other risk factors. Strategies aimed at preserving lean muscle mass could have a favorable impact on the course of disease. Disclosure of Interest None declared
- 1 June 2015
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 74 (Suppl 2) , 1022-1023
AB0388 A Reduced Lean Body Mass is Associated with a More Severe Joint Damage in Patients with Rheumatoid Arthritis (RA)
Background In Rheumatoid Arthritis (RA) alterations in the amount and distribution of fat and lean mass result in abnormal body composition phenotypes probably as a consequence of persistent inflammatory state. Lower lean mass and the sarcopenia phenotype have been associated with disability previously. Objectives The aim of this study was to determine whether a reduced Lean Body Mass (LBM) is associated with a more severe joint damage in RA Methods A cross-sectional study, conducted in consecutive established RA woman patients seen in our Rheumatology Department between 2012 and 2014. RA was defined using the ACR 1987 criteria. Patients with overlap syndrome (except Sjogren), prosthetic or metallic elements, infections, trauma/ recent surgery, cancer, hospitalized, pregnant or weight>120 kg were excluded. An interview, chart review, physical examination and laboratory tests were performed. All subjects providing written informed consent. LBM was determined by dual X-ray absorptiometry (DXA) and was expressed as the LBM Index (kg/ m2). Joint damage (JD) was measure according to Sharp VD Heijde method (erosion, joint space narrowing and total score). The association between LBM and JD was evaluated using Pearson's correlation. Subsequently, a linear regression model was performed to evaluate the persistence of these association adjusted by age, age at diagnosis, disease duration, Socioeconomic status according to Graffar's scale, tobacco habit, ACPA title, disease activity using the DAS28 ESR, glucocorticoids use and functional capacity (MHAQ questionnaire) Results One hundred and seventy-four women patients were included. The average (SD) age was 57.7 (12.7) years. Disease duration was 14.4 (10.6) years; all patients were mestizo. ACPA title was 768.8 (1357.3) uM/L, DAS28 was 4.8 (1.3), the Sharp VD Heijde total score was 168 (93.6) and the Body Mass Index (BMI) was: 28.19 (4.81) kg/m2. The LBM was 6.03 kg/m2 (0.9) and the percentage of fat Body Mass (FBM) was 38.46 (4.56) In the univariate analysis, according to Pearson correlation Index, a lower LBM was associated with a more total (-0.27, p=0.00); erosion (-0.27, p=0.001) and space narrowing (-0.25, p=0.001) Sharp VDH scores. In the multivariate model adjusted by age, age at diagnosis, disease duration, Graffar's scale, tobacco, ACPA, DAS28, glucocorticoids use and MHAQ, these correlation persisted (erosion score: B: -0.010, p=0.002; space narrowing score: B: -0.012; p=0.002 and total score: B: -0.006 p=0.001) Conclusions A lower Lean Body Mass was associated with a more severe joint damage independently of other risk factors. Strategies aimed at preserving lean muscle mass could have a favorable impact on the course of disease. Disclosure of Interest None declared